modelG02CX01

Diagram of G02CX01

Extends from Pharmacokinetic.Models.PK_2C.

Information

name:Atosiban
ATC code:G02CX01
route:intravenous
compartments:2
dosage:6.75mg
volume of distribution:18.3L
clearance:41.8L/h
other parameters in model implementation

Atosiban is an oxytocin receptor antagonist used as a tocolytic agent, meaning it is used to suppress premature labor. It is approved in many countries in Europe, but not in the United States.

Pharmacokinetics

Pharmacokinetic parameters reported in healthy female volunteers and pregnant women between 24 and 33 weeks of gestation undergoing preterm labor, following intravenous administration.

References

  1. Goodwin, TM, et al., & Holland, ML (1995). The pharmacokinetics of the oxytocin antagonist atosiban in pregnant women with preterm uterine contractions. American journal of obstetrics and gynecology 173(3 Pt 1) 913–917. DOI:10.1016/0002-9378(95)90365-8 PUBMED:https://pubmed.ncbi.nlm.nih.gov/7573268

  2. Rasmussen, BB, et al., & Senderovitz, T (2005). Pharmacokinetic interaction studies of atosiban with labetalol or betamethasone in healthy female volunteers. BJOG : an international journal of obstetrics and gynaecology 112(11) 1492–1499. DOI:10.1111/j.1471-0528.2005.00735.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/16225568

Parameters

TypeNameDefaultDescription
Modelica.Units.SI.Massweight (from PK_1C)75patient weight (kg)
Modelica.Units.SI.SpecificVolumeVdPerKg (from PK_1C)0.9Volume of distribution (L/kg)
Modelica.Units.SI.MassFractionF (from PK_1C)0.8bioavailiability (0-1)
Pharmacolibrary.Types.ClearanceCl (from PK_1C)20clearance
Modelica.Units.SI.TimeadminTime (from PK_1C)60first administration time (s)
Modelica.Units.SI.TimeadminDuration (from PK_1C)600administration duration (s)
Modelica.Units.SI.TimeadminPeriod (from PK_1C)8*60*60period of administration (default 8 hours)(s)
Pharmacolibrary.Types.MassadminMass (from PK_1C)1000administration mass (mg)
IntegeradminCount (from PK_1C)8number of dose administered (1)
Pharmacolibrary.Types.VolumeVd (from PK_1C)VdPerKg*weightVolume of distribution (m3)
Pharmacolibrary.Types.MassConcentrationCmin (from PK_1C)0.004minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCmax (from PK_1C)0.008minimal therapeutic range
Pharmacolibrary.Types.MassConcentrationCtox_peak (from PK_1C)0.012toxicity peak level
Pharmacolibrary.Types.MassConcentrationCtox_trough (from PK_1C)0.006toxicity trough level
Pharmacolibrary.Types.VolumeVdp (from PK_2C)VdpPerKg*weightVolume of distribution (m3)
Modelica.Units.SI.SpecificVolumeVdpPerKg (from PK_2C)0.9Volume of distribution peripheral(l/kg)
Pharmacolibrary.Types.Clearancek12 (from PK_2C)1intercompartmental C-P clearance
Pharmacolibrary.Types.Clearancek21 (from PK_2C)1intercompartmental P-C clearance

Connectors

TypeNameDefaultDescription
Types.ConcentrationOutputC_central (from PK_1C)
Interfaces.ConcentrationPort_bcentralCPort (from PK_1C)
Interfaces.ConcentrationPort_bperipheralCPort (from PK_2C)
Pharmacolibrary.Types.ConcentrationOutputC_peripheral1 (from PK_2C)

Components

TypeNameDefaultDescription
Pharmacokinetic.NoPerfusedTissueCompartmentcentral (from PK_1C)
Pharmacokinetic.ClearanceDrivenEliminationelim (from PK_1C)
Sources.PeriodicDoseperiodicDose (from PK_1C)
Modelica.Units.SI.Timet1_2 (from PK_1C)elimination half-life
Pharmacolibrary.Pharmacokinetic.TransferFirstOrderNonSymtransfer (from PK_2C)
Pharmacolibrary.Pharmacokinetic.NoPerfusedTissueCompartmentperipheral (from PK_2C)

Revisions

  • 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)